Roche Delays CERA Oncology Filing Until 2009

Roche is pushing back the timeline for filing its anti-anemia drug CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the company reported Feb. 1